Association of Traumatic Brain Injury With the Risk of Developing Chronic Cardiovascular, Endocrine, Neurological, and Psychiatric Disorders.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 04 2022
01 04 2022
Historique:
entrez:
28
4
2022
pubmed:
29
4
2022
medline:
3
5
2022
Statut:
epublish
Résumé
Increased risk of neurological and psychiatric conditions after traumatic brain injury (TBI) is well-defined. However, cardiovascular and endocrine comorbidity risk after TBI in individuals without these comorbidities and associations with post-TBI mortality have received little attention. To assess the incidence of cardiovascular, endocrine, neurological, and psychiatric comorbidities in patients with mild TBI (mTBI) or moderate to severe TBI (msTBI) and analyze associations between post-TBI comorbidities and mortality. This prospective longitudinal cohort study used hospital-based patient registry data from a tertiary academic medical center to select patients without any prior clinical comorbidities who experienced TBI from 2000 to 2015. Using the same data registry, individuals without head injuries, the unexposed group, and without target comorbidities were selected and age-, sex-, and race-frequency-matched to TBI subgroups. Patients were followed-up for up to 10 years. Data were analyzed in 2021. Mild or moderate to severe head trauma. Cardiovascular, endocrine, neurologic, and psychiatric conditions were defined based on International Classification of Diseases, Ninth Revision (ICD-9) or International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10). Associations between TBI and comorbidities, as well as associations between the comorbidities and mortality, were analyzed. A total of 4351 patients with mTBI (median [IQR] age, 45 [29-57] years), 4351 patients with msTBI (median [IQR] age, 47 [30-58] years), and 4351 unexposed individuals (median [IQR] age, 46 [30-58] years) were included in analyses. In each group, 45% of participants were women. mTBI and msTBI were significantly associated with higher risks of cardiovascular, endocrine, neurologic, and psychiatric disorders compared with unexposed individuals. In particular, hypertension risk was increased in both mTBI (HR, 2.5; 95% CI, 2.1-2.9) and msTBI (HR, 2.4; 95% CI, 2.0-2.9) groups. Diabetes risk was increased in both mTBI (HR, 1.9; 95% CI, 1.4-2.7) and msTBI (HR, 1.9; 95% CI, 1.4-2.6) groups, and risk of ischemic stroke or transient ischemic attack was also increased in mTBI (HR, 2.2; 95% CI, 1.4-3.3) and msTBI (HR, 3.6; 95% CI, 2.4-5.3) groups. All comorbidities in the TBI subgroups emerged within a median (IQR) of 3.49 (1.76-5.96) years after injury. Risks for post-TBI comorbidities were also higher in patients aged 18 to 40 years compared with age-matched unexposed individuals: hypertension risk was increased in the mTBI (HR, 5.9; 95% CI, 3.9-9.1) and msTBI (HR, 3.9; 95% CI, 2.5-6.1) groups, while hyperlipidemia (HR, 2.3; 95% CI, 1.5-3.4) and diabetes (HR, 4.6; 95% CI, 2.1-9.9) were increased in the mTBI group. Individuals with msTBI, compared with unexposed patients, had higher risk of mortality (432 deaths [9.9%] vs 250 deaths [5.7%]; P < .001); postinjury hypertension (HR, 1.3; 95% CI, 1.1-1.7), coronary artery disease (HR, 2.2; 95% CI, 1.6-3.0), and adrenal insufficiency (HR, 6.2; 95% CI, 2.8-13.0) were also associated with higher mortality. These findings suggest that TBI of any severity was associated with a higher risk of chronic cardiovascular, endocrine, and neurological comorbidities in patients without baseline diagnoses. Medical comorbidities were observed in relatively young patients with TBI. Comorbidities occurring after TBI were associated with higher mortality. These findings suggest the need for a targeted screening program for multisystem diseases after TBI, particularly chronic cardiometabolic diseases.
Identifiants
pubmed: 35482306
pii: 2791599
doi: 10.1001/jamanetworkopen.2022.9478
pmc: PMC9051987
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e229478Commentaires et corrections
Type : CommentIn
Références
Transl Psychiatry. 2012 Jan 17;2:e68
pubmed: 22832730
Neurosurgery. 2021 Oct 13;89(5):810-818
pubmed: 34392366
JAMA Psychiatry. 2019 Mar 1;76(3):249-258
pubmed: 30698636
Arch Phys Med Rehabil. 2020 May;101(5):822-831
pubmed: 31917196
J Head Trauma Rehabil. 2018 Jan/Feb;33(1):15-24
pubmed: 28060201
Neurotherapeutics. 2016 Apr;13(2):403-17
pubmed: 27002812
NeuroRehabilitation. 2007;22(5):341-53
pubmed: 18162698
JAMA Neurol. 2014 Dec;71(12):1490-7
pubmed: 25347255
Brain Inj. 2007 Jan;21(1):1-9
pubmed: 17364514
J Neurotrauma. 2015 Dec 1;32(23):1893-901
pubmed: 25057965
J Neurosurg. 2018 Apr 1;:1-18
pubmed: 29701556
J Neurotrauma. 2021 Jun 1;38(13):1834-1841
pubmed: 33451255
Neurosci Biobehav Rev. 2019 Jul;102:345-361
pubmed: 31102601
BMJ. 1995 Jan 21;310(6973):170
pubmed: 7833759
J Head Trauma Rehabil. 2019 Jul/Aug;34(4):E1-E10
pubmed: 30608311
Am J Ind Med. 2019 Aug;62(8):655-662
pubmed: 31134638
Neuron. 2019 Aug 7;103(3):367-379
pubmed: 31394062
Inj Prev. 2001 Dec;7(4):334-8
pubmed: 11770664
Epilepsia. 2016 Dec;57(12):1968-1977
pubmed: 27739577
Brain Inj. 2010;24(13-14):1528-38
pubmed: 21058899
Neuron. 2017 Sep 13;95(6):1246-1265
pubmed: 28910616
World Neurosurg. 2019 Feb;122:e740-e753
pubmed: 30391613
Am J Psychiatry. 2002 Aug;159(8):1315-21
pubmed: 12153823
J Neurol Neurosurg Psychiatry. 2021 May;92(5):519-527
pubmed: 33563808
Arch Phys Med Rehabil. 2010 Jan;91(1):20-9
pubmed: 20103393
BMC Res Notes. 2017 Aug 8;10(1):371
pubmed: 28789695
Neuropsychol Rev. 2016 Dec;26(4):340-363
pubmed: 27561662